| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-02-27 | Sanofi (France) Lonza (Switzerland) | large-scale mammalian cell culture facility for monoclonal antibody production in Visp (Switzerland) | joint-venture agreement | Technology - Services | Joint-venture agreement | |
| 2017-02-27 | Pieris (Germany) Aska Pharmaceutical (Japan) | PRS-080 | anemia | development - licensing - commercialisation | Hematological diseases | Licensing agreement |
| 2017-02-27 | Molmed (Italy) Rocket Pharma (USA - NY) | lentiviral vectors | Fanconi anemia | development - manufacturing - production - services contract | Rare diseases - Genetic diseases | Development agreement |
| 2017-02-27 | Recordati (Italy) Meyer Hospital (Italy) | retinopathy of prematurity | collaboration | Rare diseases - Ophtalmological diseases | Collaboration agreement | |
| 2017-02-27 | BMS (USA - NY) Exelixis (USA - CA) | Cabometyx™ (cabozantinib) with Opdivo® (nivolumab) alone or in combination with Yervoy® (ipilimumab) | first-line renal cell carcinoma | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-02-27 | Exelixis (USA - CA) Roche (Switzerland) | cabozantinib and atezolizumab | locally advanced or metastatic solid tumors | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-02-24 | Daiichi Sankyo (Japan) | restructuring | Restructuring | |||
| 2017-02-23 | MDxHealth (Belgium) Istituto Diagnostico Varelli (Italy) | SelectMDx™ for Prostate Cancer test | prostate cancer | distribution |
Cancer - Oncology - Diagnostic | Distribution agreement |
| 2017-02-23 | Novasep (France) | antibody-drug conjugate (ADC) bioconjugation unit | opening of new premises |
Technology - Services | Opening of new premises | |
| 2017-02-23 | Celgene (USA - NJ) | chief operating officer | nomination | Nomination | ||
| 2017-02-22 | Auris Medical (Switzerland) King's College London (UK) | specific small molecules for Auris Medical's AM-102 project | tinnitus | R&D - research | Otorhinolaryngology | R&D agreement |
| 2017-02-22 | 23andMe (US - CA) Celmatix (USA - NY) | fertility research community | collaboration | Women health - Fertility | Collaboration agreement | |
| 2017-02-21 | BMS (USA - NY) | nomination |
Nomination | |||
| 2017-02-21 | Cardiabase by Banook Group (France) | canadian subsidiary | establishment of a new subsidiary |
Technology - Services | Establishment of a new subsidiary in the US | |
| 2017-02-21 | Neovacs (France) BioSense Global (USA - NJ) | IFN alpha Kinoid | lupus, dermatomyositis | development - commercialisation | Autoimmune diseases - Dermatological diseases - Inflammatory diseases | Development agreement |
| 2017-02-21 | Actinium Pharmaceuticals (USA - NJ) | nomination | Cancer - Oncology | Nomination | ||
| 2017-02-21 | Biophytis (France) | opening of new premises | Ageing diseases - Muscle disorders - Ophtalmological diseases | Opening of new premises | ||
| 2017-02-21 | Genexine (Republic of Korea) CMC Biologics (Denmark - USA) | GX-H9 - recombinant growth hormone fused to hyFc | manufacturing - bioproduction | Production agreement | ||
| 2017-02-20 | AstraZeneca (UK) TerSera Therapeutics (USA) | Zoladex® (goserelin acetate implant) | prostate cancer, breast cancer, benign gynaecological disorders | commercialisation |
Cancer - Oncology - Women health | Commercialisation agreement |
| 2017-02-18 | Txcell (France) | HLA-A2 CAR lentiviral vector | services | Services contract |
